Investor Presentation - First Six Months of 2021

51 Investor presentation First six months of 2021 Novo Nordisk® Semaglutide 2.0 mg s.c. and high dose oral sema hold potential to bring patients needing treatment intensification to target Phase 3 trial, SUSTAIN FORTE, completed and label application Phase 3 trial with oral semaglutide 25 mg and 50 mg in T2D has been initiated submitted in the EU and the US1 Estimand Trial product estimand Treatment policy estimand Semaglutide 50 mg Once-weekly 2.0 mg 1.0 mg 2.0 mg 1.0 mg Semaglutide 25 mg semaglutide HbA1c 2.2%* 1.9% 2.1%* 1.9% reduction Semaglutide 14 mg Body weight 6.9* 6.0 6.4 5.6 Dose escalation reduction (kg) HbA1c < 7.0%2 68% 58% Efficacy • Semaglutide 2.0 mg s.c. showed superior HbA1c reduction with more patients reaching target¹ versus semaglutide 1.0 mg s.c. • Safety Semaglutide 2.0 mg appeared to have a safe and well-tolerated profile Gastrointestinal adverse events were similar for semaglutide 2.0 mg . Nausea rates around 15% • Treatment discontinuation rates below 5% Label expansion applications submitted in both the EU and the US 1 Refusal to file received in March 2021. Resubmitted on 28 May 2021; 2 ADA recommended treatment target *Statistically significant S.c.: subcutaneous; Sema: Semaglutide; T2D: Type 2 diabetes Maintenance Primary endpoint after 52 weeks 68 weeks on-treatment 5-weeks Follow-up • Objective Trial will assess efficacy for patients in need of improved outcomes Primary endpoint Confirm superiority of semaglutide 25 mg and 50 mg once-daily versus oral semaglutide 14 mg on HbA1c reduction

View entire presentation